The trading price of Abbvie Inc (NYSE:ABBV) closed lower on Monday, April 01, closing at $180.76, -0.74% lower than its previous close.
The company’s P/E ratio in the trailing 12-month period was 66.45, while its 5Y monthly beta was 0.56. In examining the 52-week price action we see that the stock hit a 52-week high of $182.89 and a 52-week low of $130.96. Over the past month, the stock has gained 2.68% in value.
Abbvie Inc, whose market valuation is $319.31 billion at the time of this writing, is expected to release its quarterly earnings report Apr 25, 2024 – Apr 29, 2024. The dividend yield on the company stock is 3.31%, while its Forward Dividend ratio is 5.99. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $2.33 per share this quarter, however they have predicted annual earnings per share of $11.19 for 2024 and $12.21 for 2025. It means analysts are expecting annual earnings per share growth of 0.70% this year and 9.10% next year.
Analysts have forecast the company to bring in revenue of $11.97 billion for the current quarter, with the likely lows of $11.86 billion and highs of $12.59 billion. The average estimate suggests sales will likely down by -2.10% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $54.56 billion. The company’s revenue is forecast to grow by 0.40% over what it did in 2024.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Abbvie Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest ABBV has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 17.92, which symbolizes a positive outlook. A quick review shows that ABBV’s price is currently 0.82% off the SMA20 and 3.52% off the SMA50. The RSI metric on the 14-day chart is currently showing 57.95, and weekly volatility stands at 0.99%. When measured over the past 30 days, the indicator reaches 1.49%. Abbvie Inc (NYSE:ABBV)’s beta value is currently sitting at 0.56, while the Average True Range indicator is currently displaying 2.58.
To see how Abbvie Inc stock has been performing in comparison to its peers in the industry, here are the numbers: ABBV stock’s performance was -0.74% in the latest trading, and 14.41% in the past year. Abbvie Inc has a P/E ratio of 66.45.
An evaluation of the daily trading volume of Abbvie Inc (NYSE:ABBV) indicates that the 3-month average is 5.66 million. However, this figure has increased over the past 10 days to an average of 5.26 million.
Currently, records show that 1.77 billion of the company’s shares remain outstanding. The insiders hold 0.11% of outstanding shares, whereas institutions hold 71.95%. The stats also highlight that short interest as of Mar 15, 2024, stood at 14.69 million shares, resulting in a short ratio of 2.43 at that time. From this, we can conclude that short interest is 0.83% of the company’s total outstanding shares. It is noteworthy that short shares in March were down slightly from the previous month’s figure, which was 14.75 million. However, since the stock’s price has seen 16.64% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
